S&P Futures
5,905.00 -1.00 (-0.02%) Dow Futures
43,567.00 +49.00 (+0.11%) Nasdaq Futures
20,448.25 -35.25 (-0.17%) Russell 2000 Futures
2,292.70 +1.50 (+0.07%) Crude Oil
69.84 +0.62 (+0.90%) Gold
2,746.00 +16.00 (+0.59%)
Pharvaris N.V. (9EN.F)
| Previous Close | 18.80 |
| Open | 18.90 |
| Bid | 18.90 x N/A |
| Ask | 20.20 x N/A |
| Day's Range | 18.90 - 18.90 |
| 52 Week Range | 13.60 - 29.60 |
| Volume | |
| Avg. Volume | 2 |
| Market Cap | 1.063B |
| Beta (5Y Monthly) | -3.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.61 |
| Earnings Date | Aug 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.14 |
GlobeNewswirePharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows: American College of Allergy, Asthma, & Immunology’s Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have
- GlobeNewswire
Pharvaris to Host Virtual Investor Event on October 23, 2024
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced it will host a virtual investor event to discuss the unmet need in both the prophylactic and on-demand treatment of HAE attacks, the potential of deucrictibant to address to needs, and the current HAE market dynamics, on Wednesday, October 23, 2024, a
